Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
Oppenheimer has reiterated its Buy rating on UroGen Pharma Ltd (URGN.US) and maintained a target price of $40. This article indicates continued confidence from Oppenheimer in UroGen Pharma's stock performance.
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $40
Oppenheimer has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and maintained a target price of $40. This indicates a continued positive outlook from the firm regarding the pharmaceutical company's future performance.
UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says
Oppenheimer reiterated its Outperform rating on UroGen Pharma (URGN) after an investor event focused on Zusduri's commercial strategy for treating low-grade intermediate-risk non muscle-invasive bladder cancer (LG-IR-NMIBC). The firm highlighted encouraging physician feedback on Zusduri's efficacy and safety, its potential to address an unmet need, and the ongoing market development efforts. With a target patient population of 80,000 in the U.S. and a Q1 sales run rate of $25 million, Oppenheimer believes the commercial strategy is on track for Zusduri.
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data By Investing.com
H.C. Wainwright maintained a Buy rating and $45 price target for UroGen Pharma (NASDAQ: URGN) following positive durability data from its Phase 3 ENVISION trial for ZUSDURI. The trial showed a 64.5% duration of response at 36 months in patients who achieved a complete response, aligning with strong analyst sentiment and the company's impressive gross profit margin. Additionally, UroGen reported strong Q1 2026 earnings, exceeding revenue and EPS forecasts, and positive durability results from its UTOPIA trial for UGN-103.
H.C. Wainwright reiterates UroGen Pharma stock rating on durability data
H.C. Wainwright reiterated a Buy rating and $45 price target on UroGen Pharma (NASDAQ:URGN) after new durability data from the Phase 3 ENVISION trial for ZUSDURI showed a 64.5% duration of response at 36 months. This follows the company's Q1 2026 earnings beat and promising results from both UTOPIA and ENVISION trials, reflecting strong progress in their bladder cancer treatments.
A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data
UroGen Pharma (URGN) is currently undervalued by 20.3% against a fair value estimate of $36.11, despite a recent 90-day stock return of 43.18%. This follows positive Phase 3 data for UGN-103 in bladder cancer, showing 94.5% six-month durability of response, similar to ZUSDURI. The company's valuation at $1.4 billion and trading at $28.78 suggests a potential mispricing, though significant execution risks, including operating losses and high expense guidance, remain.
A Look At UroGen Pharma (URGN) Valuation After New UGN-103 And ZUSDURI Bladder Cancer Data
UroGen Pharma (URGN) is generating interest after new Phase 3 data for UGN-103 showed strong durability in bladder cancer, mirroring previous ZUSDURI results. Despite a recent 90-day share price surge of 43.18%, the stock is considered undervalued with a fair value of $36.11 against its current $28.78. The company's valuation is driven by the potential of its minimally invasive therapies, but it faces execution risks due to operating losses and revenue concentration.
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma Ltd. announced that its UGN-103 achieved a 94.5% durability of response at six months in the Phase 3 UTOPIA trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). These results are consistent with their FDA-approved ZUSDURI, reinforcing UGN-103's potential as a new standard of care. The company plans to submit a New Drug Application for UGN-103 in Q3 2026, leveraging its streamlined manufacturing and simplified reconstitution while maintaining its proprietary RTGel technology.
How Strong UGN-103 Phase 3 Durability Data At UroGen Pharma (URGN) Has Changed Its Investment Story
UroGen Pharma recently released strong six-month durability data for UGN-103 in Phase 3 UTOPIA and updated long-term data for ZUSDURI in bladder cancer, showing potential for non-surgical treatments. These results reinforce the company's investment narrative, supporting a planned NDA filing for UGN-103 in Q3 2026, though near-term risks involving operating losses and cash runway persist. Analysts have varied optimistic outlooks on future revenue and earnings, with some predicting significant upside if reimbursement challenges and operating losses mitigate faster than anticipated.
Why (URGN) Price Action Is Critical for Tactical Trading
This article analyzes Urogen Pharma Ltd. (NASDAQ: URGN) stock, highlighting a critical weak near-term sentiment that could precede shifts in mid and long-term outlook. It identifies a significant risk-reward short setup with a 17.9% downside target versus 0.3% risk, indicating a mid-channel oscillation pattern. The report provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
UroGen Moves Toward FDA Filing For UGN-103
UroGen announced positive six-month durability results from its Phase III UTOPIA trial for UGN-103. These results are a significant step for the company as it moves towards filing with the FDA for UGN-103. The drug candidate targets cancer, and these trial results are crucial for its potential approval and subsequent market launch.
Paradigm reports 1.7M-share stake in UroGen (URGN) in 13G/A
Paradigm BioCapital entities have reported passive beneficial ownership in UroGen Pharma Ltd. (URGN) through a Schedule 13G/A filing. The filing shows Paradigm BioCapital Advisors and related parties holding 1,703,949 shares (3.5% of the class), and Paradigm BioCapital International Fund Ltd. holding 1,501,473 shares (3.1% of the class), as of March 31, 2026. This disclosure clarifies the ownership structure and voting/dispositive powers among the involved entities.
TD Bank subsidiary reports 2.62M UroGen shares (URGN) — 5.4%
The Toronto-Dominion Bank and its subsidiary TD Securities Inc. have reported beneficial ownership of 2,618,020 shares of UroGen Pharma Ltd. (URGN), representing 5.4% of the ordinary shares. This disclosure, made via a joint Schedule 13G filing, indicates a passive investment, with explicit disclaimers that the reporting entities are not acting as a group to control the issuer. TD Bank holds the vast majority of voting and dispositive power over these shares.
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
UroGen Pharma announced that its UGN-103 achieved a 94.5% six-month durability of response in the Phase 3 UTOPIA trial for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). These results are consistent with their FDA-approved treatment ZUSDURI, keeping UroGen on track to submit a New Drug Application for UGN-103 in Q3 2026. UGN-103 aims to build on ZUSDURI's success with streamlined manufacturing and simplified reconstitution while retaining the effective RTGel technology.
UroGen Moves Toward FDA Filing For UGN-103
UroGen announced positive six-month durability results from its Phase III UTOPIA trial for UGN-103. These results are a significant step for the company as it moves towards filing with the FDA for the drug. The article highlights UroGen's progress in developing treatments for chronic diseases.
UroGen Pharma Says ZUSDURI Shows Durable Disease-Free Outcomes at Three Years
UroGen Pharma announced that its investigational drug, ZUSDURI, demonstrated durable disease-free outcomes at the three-year mark for patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The long-term follow-up data from the Phase 3 ENVISION trial support the sustained efficacy of ZUSDURI, reinforcing its potential as a treatment option for this patient population.
Urogen Pharma Ltd - Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Urogen Pharma Ltd announced positive results from its Phase 3 Envision Trial for ZUSDURI, showing a 36-month Duration of Response of 64.5%. This news was reported by Reuters via TradingView. The brief report highlights the sustained efficacy of ZUSDURI in the trial.
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
UroGen Pharma Ltd. announced sustained efficacy for ZUSDURI in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC), reporting a 36-month duration of response of 64.5% in patients who achieved a complete response in the ENVISION trial. The median duration of response has not yet been reached, indicating prolonged disease control without the need for maintenance therapy. This positions ZUSDURI as a promising non-surgical alternative, reducing the burden of repeated surgical interventions for patients.
Cancer drug ZUSDURI leaves many bladder cancer patients disease-free for 3 years
UroGen Pharma (Nasdaq: URGN) announced updated Phase 3 ENVISION trial results for ZUSDURI in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The data showed a 64.5% 36-month duration of response among patients who achieved a complete response at three months, with the median duration not yet reached at 35.5 months of follow-up. This non-surgical treatment offers durable responses without maintenance therapy, aiming to provide an alternative to repeated TURBT procedures for LG-IR-NMIBC patients.
Earnings call transcript: UroGen Pharma beats Q1 2026 EPS forecast
UroGen Pharma (URGN) reported strong Q1 2026 results, surpassing EPS and revenue forecasts, primarily driven by the commercial success of ZUSDURI. The company achieved a 152% year-over-year revenue increase, with ZUSDURI showing robust growth in unique and repeat prescribers and a positive pre-market stock reaction. UroGen Pharma iterated its future guidance, expecting continued growth for ZUSDURI and stable performance for JELMYTO while advancing its pipeline with UGN-103 and UGN-501.
UroGen Pharma stock (IL0011408896): CMO sells 10K shares at $30
UroGen Pharma Ltd's Chief Medical Officer, Mark Schoenberg, sold 10,000 shares at approximately $30 per share on May 8, 2026, under a pre-arranged Rule 10b5-1 plan. This transaction, revealed by an SEC filing, occurred as the stock rose over 6% in recent trading. The company also reported strong Q1 2026 results with $51 million in revenue, a 152% year-over-year increase.
Urogen Pharma Insider Sold Shares Worth $300,000, According to a Recent SEC Filing
An insider at Urogen Pharma sold shares valued at $300,000, as reported in a recent SEC filing. This transaction indicates a significant insider sale within the company.
UroGen Pharma (URGN) CMO sells 10,000 shares in Rule 10b5-1 trade
UroGen Pharma Ltd.'s Chief Medical Officer, Mark Schoenberg, sold 10,000 Ordinary Shares at a weighted average price of approximately $30.00 per share. This open-market transaction was carried out under a pre-arranged Rule 10b5-1(c) trading plan adopted on August 15, 2025. Following the sale, Schoenberg directly holds 134,985 Ordinary Shares in the company.
UroGen Pharma CMO Mark Schoenberg sells $300,000 in shares
Mark Schoenberg, CMO of UroGen Pharma (NASDAQ:URGN), sold 10,000 shares worth $300,000 on May 8, 2026, as the stock traded near its 52-week high after a significant 183% return. This follows the company's strong first-quarter 2026 results, which exceeded revenue forecasts and led H.C. Wainwright to raise its price target to $45, maintaining a Buy rating.
A Look At UroGen Pharma (URGN) Valuation After Strong Recent Share Price Momentum
UroGen Pharma (URGN) has experienced significant share price momentum, with strong returns over the past month, three months, and year. Despite this, the company is reported to be intrinsically undervalued by 89%, with a fair value of $36.11 against its current trading price of $26.59. This valuation hinges on assumptions of rapid revenue growth, improved margins, and successful market penetration of its ZUSDURI therapy, though potential operating losses and capital raise needs remain considerations for investors.
A Look At UroGen Pharma (URGN) Valuation After Strong Recent Share Price Momentum
UroGen Pharma (URGN) has seen significant share price momentum, with strong returns over the past month, three months, and year. Despite this, a common narrative suggests the stock is undervalued by 26.4% at a fair value of $36.11, based on assumptions of rapid revenue expansion and a shift from losses to profits, primarily driven by its ZUSDURI therapy. Investors are cautioned to weigh potential operating losses and future capital raises against the optimistic forecasts.
[144] UroGen Pharma Ltd. SEC Filing
This article announces an SEC Form 144 filing by UroGen Pharma Ltd. (URGN) on May 8, 2026, indicating a proposed sale of 10,000 shares of common stock valued at $300,048. The securities were acquired through an option exercise in January 2023 and are to be sold via RBC Capital Markets LLC on NASDAQ. The filing details the transaction and affirms that the filer has no material adverse information that has not been publicly disclosed.
Urogen Pharma stock hits 52-week high at 30.02 USD
Urogen Pharma (URGN) stock has reached a 52-week high of $30.02, trading at $30.05 with a market cap of $1.44 billion and a 149% return over the past year. Despite its high gross profit margin of nearly 90% and 53% revenue growth, InvestingPro analysis indicates the stock is currently overvalued. The biopharmaceutical firm recently reported strong Q1 2026 earnings, with revenues of $51 million surpassing analyst forecasts by 14.62%.
UroGen Pharma Ltd. (NASDAQ:URGN) Q1 2026 Earnings Call Transcript
UroGen Pharma Ltd. (NASDAQ:URGN) announced strong Q1 2026 results, driven by significant ZUSDURI revenue growth following the implementation of its permanent J-code. The company reported $29.2 million in ZUSDURI revenue, representing over 100% quarter-over-quarter growth, and $21.7 million for JELMYTO. UroGen maintains its 2026 JELMYTO sales guidance and is advancing its pipeline, including UGN-103 and UGN-501, while emphasizing ZUSDURI's potential to become a blockbuster therapy in recurrent low-grade intermediate risk non-muscle invasive bladder cancer.
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40
Oppenheimer has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and increased the price target from $33 to $40. This adjustment reflects continued analyst confidence in the company's prospects.
Oppenheimer Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Raises Target Price to $40
Oppenheimer has reiterated its Buy rating on UroGen Pharma Ltd (URGN.US) and increased the price target for the company's shares to $40. This adjustment reflects the firm's continued confidence in UroGen Pharma's financial prospects and market performance.
UroGen Q1 Review: Zusduri Launch Accelerates, With Profitability Anticipated By 2027
UroGen Pharma is reaffirmed as a Strong Buy, with a 12-month price target raised to $39/share, following robust Q1 2026 results. The company's Zusduri sales more than doubled quarter-over-quarter to $29.2M, primarily driven by a January J-code assignment, which validates its path toward profitability by 2027. This profitability is supported by high gross margins, controlled expenses, and a projected break-even at $305M in annual revenue, despite risks like execution challenges and debt.
UroGen Pharma 1Q Loss/Shr 47c >URGN
UroGen Pharma reported a first-quarter loss per share of 47 cents. This financial update is a key indicator of the company's performance during the quarter. The stock symbol for UroGen Pharma is URG.
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma announced its participation in three investor conferences in May, including the Bank of America Health Care Conference, the HC Wainwright 4th Annual BioConnect Investor Conference, and the TD Cowen 7th Annual Oncology Innovation Summit. The company, focused on urothelial and specialty cancers, will be presenting and holding 1x1 meetings, with webcasts available on its Investor Relations website.
Three May events put UroGen Pharma in front of healthcare investors
UroGen Pharma (Nasdaq: URGN) will be participating in three investor conferences in May 2026: the Bank of America Health Care Conference, the HC Wainwright 4th Annual BioConnect Investor Conference, and the TD Cowen 7th Annual Oncology Innovation Summit. The company, a biotech firm focused on urothelial and specialty cancers, will be presenting at these events in various formats including 1x1 meetings and virtual sessions. Webcasts of these presentations will be accessible on UroGen's Investor Relations website and available for replay for about 90 days.
UroGen Pharma Ltd. 1Q 2026: Revenue $50.96M, EPS ($0.47) — 10-Q Summary
UroGen Pharma Ltd. reported significant growth in its first-quarter 2026 results, with revenue surging to $50.96 million, marking a 151.6% increase year-over-year. The company also narrowed its net loss and improved its diluted EPS to ($0.47) from ($0.92) in the prior-year quarter. This growth was primarily attributed to the successful launch and commercial uptake of Zusduri, expanded commercial efforts, and key FDA approvals, with plans for further clinical and pipeline advancements in 2026.
UroGen Pharma to Present at Upcoming Investor Conferences
UroGen Pharma Ltd. will participate in three investor conferences in May: the Bank of America Health Care Conference on May 13th, the HC Wainwright 4th Annual BioConnect Investor Conference on May 19th, and the TD Cowen 7th Annual Oncology Innovation Summit on May 26th. The company plans to present information about its innovative solutions for urothelial and specialty cancers, utilizing its proprietary RTGel® platform technology. Webcasts of these presentations will be available on UroGen's Investor Relations website.
TD Cowen Maintains UroGen Pharma Ltd(URGN.US) With Buy Rating, Maintains Target Price $35
TD Cowen has reiterated its Buy rating for UroGen Pharma Ltd (URGN.US) and maintained its target price at $35. This indicates a continued positive outlook from the analyst firm on the biotechnology company's stock.
UroGen Pharma (URGN) Q1 Revenue Surge Tests Bearish Cash Runway Concerns
UroGen Pharma reported Q1 2026 revenues of US$51.0 million, a significant increase from Q1 2025, alongside a narrowing EPS loss of US$0.47. Despite this revenue surge, the company remains loss-making with a trailing twelve-month loss of US$133.2 million and faces balance sheet pressure with less than one year of cash runway and negative shareholders' equity, prompting concerns about future profitability and the need for external funding.
Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q1 Revenue $51.0M, Vs. FactSet Est of $44.8M
UroGen Pharma Ltd. (URGN) announced Q1 revenue of $51.0 million, significantly exceeding FactSet's estimate of $44.8 million. This financial beat indicates a stronger-than-expected performance for the quarter.
Earnings call transcript: UroGen Pharma surpasses Q1 2026 revenue forecasts
UroGen Pharma reported Q1 2026 revenue of $51 million, surpassing forecasts by 14.62%, and an EPS of -$0.47, better than the anticipated -$0.50. This strong performance, driven by the successful launch of ZUSDURI and its permanent J-code, led to a 5.83% increase in UroGen's stock in pre-market trading. The company projects continued growth, targeting $245.05 million in total revenue for FY 2026 and potential profitability by FY 2027.
UroGen Pharma Releases Q1 2026 Financial Results
UroGen Pharma Ltd. reported narrower-than-expected losses for Q1 2026, with a loss of $0.47 per share against an anticipated $0.49. Revenue surged by 152.0% year-over-year to $51.0 million, driven by strong performance from its cancer treatment portfolio, particularly ZUSDURI. The company issued FY26 guidance for JELMYTO product revenue between $97.0M and $101.0M, reflecting confidence in continued growth.
UroGen Pharma’s ZUSDURI™ Revenue More Than Doubles in First Quarter 2026
UroGen Pharma announced a significant increase in ZUSDURI™ revenue, which more than doubled from the previous quarter in its first quarter 2026 financial results. This growth demonstrates strong market uptake of the drug and reflects progress in the company's strategic objectives. Further details on overall financial performance and key achievements are available in their full report.
Earnings Flash (URGN) UroGen Pharma Ltd. Reports Q1 Revenue $51.0M, vs. FactSet Est of $44.8M
UroGen Pharma Ltd. (URGN) announced Q1 revenue of $51.0 million, surpassing the FactSet estimate of $44.8 million. This news followed an earlier report of a narrower Q1 net loss of $0.47 a share, which also beat the FactSet estimate of a $0.48 loss. The positive financial results contributed to a rise in UroGen Pharma shares.
UroGen Pharma (URGN) surges to 152% Q1 revenue growth and trims loss
UroGen Pharma reported a significant Q1 2026 revenue increase of 152% year-over-year, reaching $50.9 million, primarily driven by the strong commercial launch of ZUSDURI and continued growth of JELMYTO. The company also substantially reduced its net loss to $23.6 million from $43.8 million in Q1 2025. UroGen reaffirmed its 2026 JELMYTO revenue guidance and outlined progress in its pipeline, including UGN-103, UGN-104, and UGN-501.
UroGen earnings in focus: Can ZUSDURI drive commercial momentum?
UroGen Pharma Ltd. is set to announce its first-quarter results, with analysts expecting a loss of $0.50 per share on revenue of $44.46 million. Investors will be closely watching ZUSDURI revenue acceleration following a key reimbursement milestone (J-code implementation) and whether the company's revenue growth outpaces its expenses. Wall Street remains largely optimistic, with a mean price target suggesting a 45% upside.
Urogen Pharma (URGN) Projected to Post Quarterly Earnings on Wednesday
Urogen Pharma (URGN) is set to report its Q1 2026 earnings before market open on Wednesday, May 6th, with analysts anticipating a loss of ($0.4824) per share and revenue of $44.83 million. The company's stock recently traded around $23, and it holds a "Moderate Buy" consensus rating with an average price target of $34.13 from Wall Street analysts. Recent insider selling has occurred, while institutional investors hold a significant majority of the shares.
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
UroGen Pharma Ltd. (Nasdaq: URGN) announced it will release its first quarter 2026 financial results on Wednesday, May 6th, 2026, before the stock market opens. This will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time, accessible via the company's Investor Relations website. UroGen Pharma focuses on developing innovative solutions for urothelial and specialty cancers using its RTGel® sustained-release technology.
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
UroGen Pharma Ltd. announced it will report its first quarter 2026 financial results on Wednesday, May 6th, 2026, before the stock market opens. This will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time to discuss the results. The company, focused on urothelial and specialty cancers, will make a replay of the webcast available on its Investor Relations website for approximately 30 days.
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
UroGen Pharma Ltd. (Nasdaq: URGN) announced it will report its first quarter 2026 financial results on Wednesday, May 6th, 2026, before the stock market opens. This will be followed by a live audio webcast and conference call at 10:00 AM ET. A replay of the webcast will be available on UroGen's Investor Relations website for approximately 30 days.
